Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies

Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine

Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · see citing works

Implications of Normal Brain Development for the Pathogenesis of Schizophrenia

Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724 · see citing works

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses

Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · see citing works

Psychopharmacology: The Fourth Generation of Progress

Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985 · see citing works

Recent advances in the phencyclidine model of schizophrenia

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · see citing works

From motivation to action: Functional interface between the limbic system and the motor system

MOGENSON, G., JONES, D., & YIM, C. (1980) · Progress in Neurobiology · doi:10.1016/0301-0082(80)90018-0 · Cited by 2,331 · see citing works

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220 · see citing works

Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse Brain

Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,156 · see citing works

Dopamine in schizophrenia: a review and reconceptualization

Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,021 · see citing works

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020 · see citing works

Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia

Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,019 · see citing works

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia

Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831 · see citing works

Learning and Memory Functions of the Basal Ganglia

Packard, M. G., & Knowlton, B. J. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142937 · Cited by 1,717 · see citing works

Glutamate receptor dysfunction and schizophrenia

Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · see citing works

Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine

Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,420 · see citing works

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352 · see citing works

The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia

Jentsch, J., & Roth, R. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,349 · see citing works

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · see citing works

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method

Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · see citing works

Does Fast Dissociation From the Dopamine D ₂ Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis

Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140 · see citing works

Relationship Between Dopamine D ₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090 · see citing works

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,060 · see citing works

The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones

Smith, A. D., & Bolam, J. P. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90106-k · Cited by 1,040 · see citing works

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,022 · see citing works

Increased baseline occupancy of D ₂ receptors by dopamine in schizophrenia

Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · see citing works

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · see citing works

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

Shapiro, D. A., Renock, S. M., Arrington, E. G., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. B. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 971 · see citing works

Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens

Nicola, S. M., Surmeier, D. J., & Malenka, R. C. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.185 · Cited by 931 · see citing works

Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia

Lahti, A. C., Koffel, B., LaPorte, D. J., & Tamminga, C. A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921 · see citing works

The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia

GOFF, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 914 · see citing works

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · see citing works

Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

Abi-Dargham, A., Gil, R. B., Krystal, J., Baldwin, R., Seibyl, J., Bowers, M., van Dyck, C., Charney, D., Innis, R., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 860 · see citing works

D1 receptors in prefrontal cells and circuits

Goldman-Rakic, P. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00045-4 · Cited by 807 · see citing works

The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons

Wilson, C. J., & Kawaguchi, Y. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-07-02397.1996 · Cited by 798 · see citing works

Serotonin receptors : their key role in drugs to treat schizophrenia

Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 778 · see citing works

Increased dopamine transmission in schizophrenia: relationship to illness phases.

Laruelle, M., Abi-Dargham, A., Gil, R. B., Kegeles, L., & Innis, R. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00067-0 · Cited by 744 · see citing works

Prefrontal Dopamine D₁Receptors and Working Memory in Schizophrenia

Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724 · see citing works

An anatomy of schizophrenia?

Stevens, J. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.04200020023003 · Cited by 719 · see citing works

Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715 · see citing works

Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia

Kapur, S., Zipursky, R. B., & Remington, G. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 711 · see citing works

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET

Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (1997) · Nature · doi:10.1038/385634a0 · Cited by 710 · see citing works

Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs

Farde, L. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250087012 · Cited by 696 · see citing works

Clozapine

Oates, J. A., Wood, A. J. J., Baldessarini, R. J., & Frankenburg, F. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241107 · Cited by 689 · see citing works

Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons

Chiodo, L. A., & Bunney, B. (1983) · Journal of Neuroscience · doi:10.1523/jneurosci.03-08-01607.1983 · Cited by 680 · see citing works

D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia

Tsai, G. E., Yang, P., Chang, Y., & Chong, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 676 · see citing works

Effects of Ketamine in Normal and Schizophrenic Volunteers

Lahti, A. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674 · see citing works

Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia

Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652 · see citing works

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

White, F. J., & Wang, R. Y. (1983) · Science · doi:10.1126/science.6136093 · Cited by 590 · see citing works

D-serine added to antipsychotics for the treatment of schizophrenia

Tsai, G. E., Yang, P., Chung, L.-C., LANGE, N. D., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 572 · see citing works

Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats

PYCOCK, C., Kerwin, R. W., & Carter, C. J. (1980) · Nature · doi:10.1038/286074a0 · Cited by 550 · see citing works

Provocative tests with psychostimulant drugs in schizophrenia

Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 535 · see citing works

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients

Nordström, A., Farde, L., Wiesel, F., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527 · see citing works

Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D ₂ Receptor Parameter Measurements in Ventral Striatum

Mawlawi, O., Martinez, D., Slifstein, M., Broft, A., Chatterjee, R., Hwang, D.-R., Huang, Y., Simpson, N., Ngo, K., Van Heertum, R., et al. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200109000-00002 · Cited by 525 · see citing works

Schizophrenia

Carpenter, W. T., & Buchanan, R. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403103301006 · Cited by 510 · see citing works

D1Receptor Activation Enhances Evoked Discharge in Neostriatal Medium Spiny Neurons by Modulating an L-Type Ca2+Conductance

Hernández‐López, S., Bargas, J., Surmeier, D. J., Reyes, A., & Galarraga, E. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-09-03334.1997 · Cited by 495 · see citing works

5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release

Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 495 · see citing works

Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia

Heresco‐Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G. S., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487 · see citing works

Neuroleptics increase C-FOS expression in the forebrain: Contrasting effects of haloperidol and clozapine

Robertson, G. S., & Fibiger, H. C. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90054-6 · Cited by 474 · see citing works

A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia

GOFF, D. C., Tsai, G. E., Levitt, J. J., AMICO, E. T., Manoach, D. S., Schoenfeld, D., Hayden, D. L., McCarley, R. W., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436 · see citing works

Catecholamines in the Brain as Mediators of Amphetamine Psychosis

Snyder, S. H. (1972) · Archives of General Psychiatry · doi:10.1001/archpsyc.1972.01750260021004 · Cited by 432 · see citing works

Lamina-Specific Alterations in the Dopamine Innervation of the Prefrontal Cortex in Schizophrenic Subjects

Akil, M., Pierri, J. N., Whitehead, R. E., Edgar, C. L., Mohila, C., Sampson, A. R., & Lewis, D. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1580 · Cited by 393 · see citing works

Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia

Dolan, R. J., Fletcher, P. C., Frith, C., Friston, K. J., Frackowiak, R. S. J., & Grasby, P. M. (1995) · Nature · doi:10.1038/378180a0 · Cited by 375 · see citing works

Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane

Dunah, A. W., & Standaert, D. G. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05546.2001 · Cited by 374 · see citing works

5-HT₂and D₂Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation

Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370 · see citing works

Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability

DeLeon, A., Patel, N. C., & Crismon, M. L. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90066-5 · Cited by 364 · see citing works

Dopaminergic control of synaptic plasticity in the dorsal striatum

Centonze, D., Picconi, B., Gubellini, P., Bernardi, G., & Calabresi, P. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01485.x · Cited by 361 · see citing works

Amelioration of negative symptoms in schizophrenia by glycine

Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco‐Levy, U., & Lindenmayer, J. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 353 · see citing works

The basal ganglia and cognitive pattern generators

Graybiel, A. M. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.3.459 · Cited by 351 · see citing works

Dopamine and N-Methyl-D- Aspartate Receptor Interactions in the Neostriatum

Cepeda, C., & Levine, M. S. (1998) · Developmental Neuroscience · doi:10.1159/000017294 · Cited by 350 · see citing works

Elevated dopa decarboxylase activity in living brain of patients with psychosis

Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., & Dyve, S. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11651 · Cited by 342 · see citing works

Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?

Matthysse, S. (1973) · PubMed · Cited by 338 · see citing works

Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment

Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336 · see citing works

Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET.

Lindström, L., Gefvert, O., Hagberg, G., Lundberg, T., Bergström, M., Hartvig, P., & Långström, B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00109-2 · Cited by 332 · see citing works

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Seeger, T., Seymour, P. A., Schmidt, A. W., Zorn, S. H., Schulz, D. W., Lebel, L. A., McLean, S., Guanowsky, V., Howard, H. R., & Lowe, J. A., III (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12023-5 · Cited by 322 · see citing works

Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients

Hietala, J. A., Syvälahti, E. K. G., Kuoppamäki, M., Hietala, J., Syvälahti, E. K. G., Haaparanta‐Solin, M., Kuoppamäki, M., Ruotsalainen, U., Vuorio, K. A., Räkköläinen, V., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91801-9 · Cited by 321 · see citing works

Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride

Yokoi, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00304-4 · Cited by 315 · see citing works

Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity.

Robertson, G. S., Matsumura, H., & Fibiger, H. C. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23800-9 · Cited by 311 · see citing works

Dopamine, the prefrontal cortex and schizophrenia

Knable, M. B., & Weinberger, D. R. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100205 · Cited by 304 · see citing works

Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress

Deutch, A. Y., Clark, W. A., & Roth, R. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)91557-w · Cited by 302 · see citing works

Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system

Andén, N., & Stock, G. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10025.x · Cited by 294 · see citing works

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

Kapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 285 · see citing works

Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs

Grace, A. A., Bunney, B. S., Moore, H. M., & Todd, C. L. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10064-3 · Cited by 284 · see citing works

The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia

Daniel, D., Weinberger, D. R., Jones, D. W., Zigun, J. R., Coppola, R., Handel, S. F., Bigelow, L. B., Goldberg, T., Berman, K. F., & Kleinman, J. E. (1991) · Journal of Neuroscience · doi:10.1523/jneurosci.11-07-01907.1991 · Cited by 277 · see citing works

Dopamine Enhancement of NMDA Currents in Dissociated Medium-Sized Striatal Neurons: Role of D1 Receptors and DARPP-32

Flores‐Hernández, J., Cepeda, C., Hernández, E., Calvert, C. R., Jokel, E. S., Fienberg, A. A., Greengard, P., & Levine, M. S. (2002) · Journal of Neurophysiology · doi:10.1152/jn.00361.2002 · Cited by 270 · see citing works

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

Wolkin, A., Barouche, F., Wolf, A. P., Rotrosen, J., Fowler, J. S. L., Shiue, C., Cooper, T. B., & Brodie, J. D. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.7.905 · Cited by 258 · see citing works

Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia

Heresco‐Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · The British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255 · see citing works

Mechanisms of action of atypical antipsychotic drugs

Deutch, A. Y., Moghaddam, B., Innis, R. B., Krystal, J. H., Aghajanian, G. K., Bunney, B. S., & Charney, D. S. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90030-u · Cited by 253 · see citing works

Opposite Influences of Endogenous Dopamine D1and D2Receptor Activation on Activity States and Electrophysiological Properties of Striatal Neurons: Studies CombiningIn VivoIntracellular Recordings and Reverse Microdialysis

West, A. R., & Grace, A. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00294.2002 · Cited by 252 · see citing works

Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.

McGowan, S., Lawrence, A., Sales, T., Quested, D., & Grasby, P. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.2.134 · Cited by 251 · see citing works

Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum

Ichikawa, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00312-8 · Cited by 248 · see citing works

[Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)].

Delay, J., Deniker, P., & Harl, J. M. (1952) · PubMed · Cited by 244 · see citing works

Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia

Hietala, J. A., Syvälahti, E. K. G., Vilkman, H., Vuorio, K. A., Räkköläinen, V., Bergman, J. R., Haaparanta‐Solin, M., Solin, O. H., Kuoppamäki, M., Eronen, E., et al. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00113-3 · Cited by 243 · see citing works

Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action

Deutch, A. Y., Lee, M. C., & Iadarola, M. J. (1992) · Molecular and Cellular Neuroscience · doi:10.1016/1044-7431(92)90030-6 · Cited by 240 · see citing works

Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs

Andén, N. (1972) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1972.tb08912.x · Cited by 237 · see citing works

Agranulocytosis during treatment with clozapine

Id�np��n-Heikkil�, J., Alhava, E., Olkinuora, M., & PALVA, I. P. (1977) · European Journal of Clinical Pharmacology · doi:10.1007/bf00606409 · Cited by 236 · see citing works

Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson' disease

Starr, M. S. (1995) · Synapse · doi:10.1002/syn.890190405 · Cited by 214 · see citing works

Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations

Yamamoto, B., & Cooperman, M. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-07-04159.1994 · Cited by 203 · see citing works

Facilitated Glutamatergic Transmission in the Striatum of D2Dopamine Receptor-Deficient Mice

Cepeda, C., Hurst, R. S., Altemus, K. L., Flores‐Hernández, J., Calvert, C. R., Jokel, E. S., Grandy, D. K., Low, M. J., Rubinstein, M., Ariano, M. A., et al. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.2.659 · Cited by 203 · see citing works

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

Rollema, H., Lu, Y., Schmidt, A. W., & Zorn, S. H. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)81951-6 · Cited by 203 · see citing works

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

Pilowsky, L. S., Murray, R. M., Kerwin, R. W., Costa, D. C., Ell, P. J., & Verhoeff, N. P. L. G. (1992) · The Lancet · doi:10.1016/0140-6736(92)90467-h · Cited by 202 · see citing works

Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices

Levine, M. S., Li, Z., Cepeda, C., Cromwell, H. C., & Altemus, K. L. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199609)24:1 · Cited by 200 · see citing works

Adjunctive high-dose glycine in the treatment of schizophrenia

Javitt, D. C., Silipo, G. S., Cienfuegos, A., Shelley, A. M., Bark, N. M., Park, M., Lindenmayer, J., Suckow, R. F., & Zukin, S. R. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002590 · Cited by 199 · see citing works

5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

Rollema, H., Lu, Y., Schmidt, A. W., Sprouse, J. S., & Zorn, S. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00850-7 · Cited by 195 · see citing works

A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone

Mamo, D. C., Kapur, S., Shammi, C., Papatheodorou, G. N., Mann, S. W., Therrien, F., & Remington, G. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.818 · Cited by 189 · see citing works

Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum

Kötter, R. (1994) · Progress in Neurobiology · doi:10.1016/0301-0082(94)90037-x · Cited by 186 · see citing works

Limbic selectivity of clozapine

Pilowsky, L. S., Mulligan, R. S., Acton, P. D., Ell, P. J., Costa, D. C., & Kerwin, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63079-6 · Cited by 176 · see citing works

The Relationship between Dorsolateral Prefrontal Neuronal N-Acetylaspartate and Evoked Release of Striatal Dopamine in Schizophrenia

Bertolino, A., Breier, A., Callicott, J., Adler, C., Mattay, V., Shapiro, M., Frank, J., Pickar, D., & Weinberger, D. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00096-2 · Cited by 172 · see citing works

PET Study of D1 Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia

Karlsson, P., Farde, L., Halldin, C., & Sedvall, G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.761 · Cited by 172 · see citing works

Time course of central nervous dopamine-D 2 and 5-HT 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel ® ) in patients with schizophrenia

Gefvert, O., Bergström, M., Långström, B., Lundberg, T., Lindström, L., & Yates, R. A. (1998) · Psychopharmacology · doi:10.1007/s002130050492 · Cited by 169 · see citing works

Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

Xiberas, X., Martinot, J., Mallet, L., Eric Artiges, A., Loc’h, C., Maziere, B., & Martinot, M. P. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.6.503 · Cited by 169 · see citing works

The Synaptic Hypothesis of Schizophrenia

Frankle, W. G., Lerma, J., & Laruelle, M. A. (2003) · Neuron · doi:10.1016/s0896-6273(03)00423-9 · Cited by 167 · see citing works

Placebo-Controlled Trial of d -Cycloserine Added to Conventional Neuroleptics, Olanzapine, or Risperidone in Schizophrenia

Heresco‐Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G. S., & Javitt, D. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.480 · Cited by 167 · see citing works

A historical perspective of clozapine.

Hippius, H. (1999) · PubMed · Cited by 165 · see citing works

Presynaptic dopaminergic function in the striatum of schizophrenic patients

Dao-Castellana, M. H., Martinot, M. P., Hantraye, P., Attar-Levy, D., Rémy, P., Crouzel, C., Eric Artiges, A., Féline, A., Syrota, A., & Martinot, J. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00102-8 · Cited by 160 · see citing works

Behavior and the basal ganglia.

Saint‐Cyr, J. A., Taylor, A. E., & Nicholson, K. (1995) · PubMed · Cited by 155 · see citing works

Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs

Leveque, J., Macias‐Konstantopoulos, W., Rajadhyaksha, A. M., Carlson, R. R., Barczak, A. K., Kang, S., Li, X., Coyle, J. T., Huganir, R. L., Heckers, S., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04011.2000 · Cited by 148 · see citing works

Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients

Karlsson, P., Farde, L., Härnryd, C., Sedvall, G., Smith, L. A., & Wiesel, F. ‐. (1995) · Psychopharmacology · doi:10.1007/bf02246068 · Cited by 148 · see citing works

Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices

Levine, M. S., Li, S., Cepeda, C., Cromwell, H. C., & Altemus, K. L. (1996) · Synapse · doi:10.1002/syn.890240102 · Cited by 139 · see citing works

Pharmacologic strategies for augmenting cognitive performance in schizophrenia

Friedman, J. I., Temporini, H. D., & Davis, K. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00287-x · Cited by 138 · see citing works

Dopamine-mediated regulation of striatal neuronal and network interactions

Onn, S., West, A. R., & Grace, A. A. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00020-3 · Cited by 135 · see citing works

Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum

Westerink, B. H. C., Kawahara, Y., Boer, P. D., Geels, C., Vries, J. B. D., Wikström, H., Kalkeren, A. A. V., Vliet, B. J. V., Kruse, C. G., & Long, S. K. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00935-3 · Cited by 120 · see citing works

Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients

Bressan, R. A., Erlandsson, K., JONES, H. M., Mulligan, R. S., Flanagan, R. J., Ell, P. J., & Pilowsky, L. S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1413 · Cited by 111 · see citing works

Dissociation of Haloperidol, Clozapine, and Olanzapine Effects on Electrical Activity of Mesocortical Dopamine Neurons and Dopamine Release in the Prefrontal Cortex

Gessa, G. L. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00087-7 · Cited by 110 · see citing works

CNS stimulants as tools in the study of schizophrenia

Angrist, B., & van Kammen, D. P. (1984) · Trends in Neurosciences · doi:10.1016/s0166-2236(84)80062-4 · Cited by 100 · see citing works

Mesocortical Dopaminergic Function and Human Cognition

Weinberger, D. R., Berman, K. F., & Chase, T. N. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb42117.x · Cited by 100 · see citing works

Dopamine and the pharmacology of schizophrenia: The state of the evidence

Matthysse, S. (1974) · Journal of Psychiatric Research · doi:10.1016/0022-3956(74)90081-8 · Cited by 99 · see citing works

No Support for Regional Selectivity in Clozapine-Treated Patients: A PET Study With [ 11 C]Raclopride and [ 11 C]FLB 457

Talvik, M., Nordström, A., Nyberg, S., Olsson, H., Halldin, C., & Farde, L. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.926 · Cited by 98 · see citing works

In Vivo Extrastriatal and Striatal D2 Dopamine Receptor Blockade by Amisulpride in Schizophrenia

Xiberas, X., Martinot, J., Mallet, L., Eric Artiges, A., Canal, M., Loc’h, C., Maziere, B., & Martinot, M. P. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00013 · Cited by 95 · see citing works

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

den Boer, J. A., van Megen, H. J. G. M., Slaap, B. R., Westenberg, H. G. M., Fleischhacker, W. W., Louwerens, J. W., Burrows, G. D., & Srivastava, O. N. (1995) · Psychopharmacology · doi:10.1007/bf02246069 · Cited by 95 · see citing works

Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in Schizophrenia

Guo, N., Hwang, D., Lo, E., Huang, Y.-Y., Laruelle, M. A., & Abi‐Dargham, A. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300224 · Cited by 93 · see citing works

Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

Duncan, G. E., Zorn, S. J., & Lieberman, J. A. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000581 · Cited by 90 · see citing works

Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target

Remington, G. J. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0334 · Cited by 89 · see citing works

Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade

Tauscher‐Wisniewski, S., Kapur, S., Tauscher, J. T., Jones, C., Daskalakis, Z. J., Papatheodorou, G. N., Epstein, I., Christensen, B. K., & Zipursky, R. B. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1106 · Cited by 88 · see citing works

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [ 123 I]epidepride single photon emission tomography (SPET) study

Bigliani, V., Mulligan, R. S., Acton, P. D., Ohlsen, R. I., Pike, V. W., Ell, P. J., Gacinovic, S., Kerwin, R. W., & Pilowsky, L. S. (2000) · Psychopharmacology · doi:10.1007/s002130000435 · Cited by 86 · see citing works

Managing patients with “treatment‐resistant” schizophrenia

Pantelis, C., & Lambert, T. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05310.x · Cited by 85 · see citing works

Clozapine Preferentially Increases Dopamine Release in the Rhesus Monkey Prefrontal Cortex Compared with the Caudate Nucleus

Youngren, K. D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00082-7 · Cited by 85 · see citing works

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia

Heresco‐Levy, U., Javitt, D. C., Ermilov, M., Silipo, G. S., & Shimoni, J. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798001242 · Cited by 85 · see citing works

Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo

Stephenson, C., Bigliani, V., Jones, H., Mulligan, R. S., Acton, P. D., Visvikis, D., Ell, P. J., Kerwin, R. W., & Pilowsky, L. S. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.408 · Cited by 82 · see citing works

Differential Effects of Locally Administered Clozapine and Haloperidol on Dopamine Efflux in the Rat Prefrontal Cortex and Caudate‐Putamen

Pehek, E. A., & Yamamoto, B. K. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63062118.x · Cited by 80 · see citing works

Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality

Heresco‐Levy, U. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.007 · Cited by 80 · see citing works

Optimizing Limbic Selective D2/D3 Receptor Occupancy by Risperidone: A [123I]-Epidepride SPET Study

Bressan, R. A., Erlandsson, K., JONES, H. M., Mulligan, R. S., Ell, P. J., & Pilowsky, L. S. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00002 · Cited by 77 · see citing works

Glutamate pharmacology and the treatment of schizophrenia: current status and future directions

Tamminga, C. A., Holcomb, H. H., Gao, X., & Lahti, A. C. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199509000-00005 · Cited by 74 · see citing works

M-100907 (Aventis).

de Paulis, T. (2001) · PubMed · Cited by 71 · see citing works

IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol

K�fferle, B., Tauscher, J. T., Asenbaum, S., Vesely, C., Podreka, I., Br�cke, T., & Kasper, S. F. (1997) · Psychopharmacology · doi:10.1007/s002130050409 · Cited by 68 · see citing works

Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by acid

Morari, M., O'Connor, W. T., Ungerstedt, U., & Fuxé, K. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90611-4 · Cited by 65 · see citing works

Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function

Kahn, R. S., Harvey, P. D., Davidson, M., Keefe, R. S. E., APTER, S., Neale, J. M., Mohs, R. C., & Davis, K. L. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90015-9 · Cited by 65 · see citing works

Striatal dopamine–NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors

Marti, M., Mela, F., Bianchi, C., Beani, L., & Morari, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01169.x · Cited by 61 · see citing works

An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states

de Beaurepaire, R., Labelle, A., Jones, B., Naber, D., & Barnes, T. R. E. (1995) · Psychopharmacology · doi:10.1007/bf02246070 · Cited by 60 · see citing works

Individual variation in D2 dopamine receptor occupancy in clozapine- treated patients

Pickar, D., Su, T.-P., Weinberger, D. R., Coppola, R., Malhotra, A. K., Knable, M. B., Lee, K. S., Gorey, J. G., Bartko, J. J., Breier, A. F., et al. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1571 · Cited by 59 · see citing works

Dopamine Transmission in the Schizophrenic Brain

Laruelle, M. A. (2003) · Wiley eBooks · doi:10.1002/9780470987353.ch20 · Cited by 53 · see citing works

Erratum Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride

(2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00439-6 · Cited by 53 · see citing works

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia

Karle, J., Lublin, H., Gerlach, J., Clemmesen, L., Hansen, L., Andersen, M. Ø., Andersen, J., Fensbo, C., Sloth-Nielsen, M., & Skrumsager, B. K. (1995) · Psychopharmacology · doi:10.1007/bf02246071 · Cited by 52 · see citing works

Schizophrenia (2nd edn). Edited by Steven R. Hirsch & Daniel R. Weinberger Oxford: Blackwell. 2003. 768 pp. £89.50 (hb). ISBN 0 632063882

Denman, A. M. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.3.280 · Cited by 52 · see citing works

Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications

Frankle, W., Gil, R. B., Hackett, E., Mawlawi, O., Zea-Ponce, Y., Zhu, Z., Kochan, L., Cangiano, C., Slifstein, M., Gorman, J., et al. (2003) · Psychopharmacology · doi:10.1007/s00213-004-1852-4 · Cited by 50 · see citing works

Clozapine: Dopamine D1Receptor Agonism in the Prefrontal Cortex as the Code to Decipher a Rosetta Stone of Antipsychotic Drugs

Ahlénius, S. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb01482.x · Cited by 50 · see citing works

Central D1- and D2-receptor occupancy during antipsychotic drug treatment

Wiesel, F., Farde, L., Nordström, A., & Sedvall, G. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90046-j · Cited by 49 · see citing works

In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs

Bigliani, V., Mulligan, R. S., Acton, P. D., Visvikis, D., Ell, P. J., Stephenson, C., Kerwin, R. W., & Pilowsky, L. S. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.175.3.231 · Cited by 47 · see citing works

Dose relationship of limbic-cortical D 2 -dopamine receptor occupancy with risperidone

Yasuno, F., Suhara, T., Okubo, Y., Sudo, Y., Inoue, M., Ichimiya, T., & Tanada, S. (2001) · Psychopharmacology · doi:10.1007/s002130000643 · Cited by 37 · see citing works

Recent Advances in the Teaching of Physics

Crew, H. (1904) · Science · doi:10.1126/science.19.482.481 · Cited by 36 · see citing works

Modulation of the ability of clozapine to facilitate NMDA‐ and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence

Ninan, I., & Wang, R. Y. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02549.x · Cited by 32 · see citing works

Chapter 32 Role of the cerebral cortex and striatum in emotional motor response

Saper, C. B. (1996) · Progress in brain research · doi:10.1016/s0079-6123(08)61886-5 · Cited by 29 · see citing works

Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics

Scherer, J., Tatsch, K., Schwarz, J., Oertel, W. H., Kirsch, M. C., & Albus, M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90076-0 · Cited by 29 · see citing works

Clozapine potently stimulates mesocortical dopamine neurons

Melis, M., Diana, M., & Gessa, G. L. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00934-0 · Cited by 28 · see citing works

Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine

Cussac, D., Pasteau, V., & Millan, M. J. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.11.077 · Cited by 24 · see citing works

Antipsychotic Drugs: Evolving Mechanisms of Action with Improved Therapeutic Benefits

Dean, B., & Scarr, E. (2004) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007043337373 · Cited by 24 · see citing works

Biphasic modulation of evoked [3H]D‐aspartate release by D‐2 dopamine receptors in rat striatal slices

Peris, J., Dwoskin, L. P., & Zahniser, N. R. (1988) · Synapse · doi:10.1002/syn.890020413 · Cited by 24 · see citing works

The Relationship Between Risperidone Plasma Levels and Dopamine D (2) Occupancy

Remington, G. J., Kapur, S., & Zipursky, R. B. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199802000-00014 · Cited by 24 · see citing works

Reevaluation of the Mesolimbic Hypothesis of Antipsychotic Drug Action

Lidsky, T. I. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.1.67 · Cited by 22 · see citing works

Is clozapine an (partial) agonist at both dopamine D 1 and D 2 receptors?

Jackson, D. M., Wikström, H., & Liao, Y. (1998) · Psychopharmacology · doi:10.1007/s002130050665 · Cited by 18 · see citing works

Partial agonistic action of clozapine at dopamine D 2 receptors in dopamine depleted animals

Ninan, I., & Kulkarni, S. (1998) · Psychopharmacology · doi:10.1007/s002130050515 · Cited by 16 · see citing works

The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue

Brisch, R., Saniotis, A., Wolf, R. J., Bielau, H., Bernstein, H., Steiner, J. H., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 520 · see citing works

Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions

Jope, R. S., & Roh, M. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382 · see citing works

Neurobiology of Dopamine in Schizophrenia

Guillin, O., Abi‐Dargham, A., & Laruelle, M. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78001-1 · Cited by 365 · see citing works

Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia

Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010144 · Cited by 351 · see citing works

Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives

Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N. G., & Sawa, A. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.016 · Cited by 313 · see citing works

A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight

Revel, F. G., Moreau, J., Pouzet, B., Mory, R., Bradaïa, A., Buchy, D., Metzler, V., Chaboz, S., Zbinden, K. G., Galley, G., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.57 · Cited by 289 · see citing works

The kynurenine pathway in schizophrenia and bipolar disorder

Erhardt, S., Schwieler, L., Imbeault, S., & Engberg, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.020 · Cited by 257 · see citing works

Dopamine D3 receptor antagonists as therapeutic agents

Joyce, J. N., & Millan, M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03491-4 · Cited by 237 · see citing works

Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection

Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 223 · see citing works

Brain Imaging of Nicotinic Receptors in Alzheimer's Disease

Wu, J., Ishikawa, M., Zhang, J., & Hashimoto, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/548913 · Cited by 209 · see citing works

Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice

Ortega-Álvaro, A., Aracil-Fernández, A., García‐Gutiérrez, M. S., Navarrete, F., & Manzanares, J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.34 · Cited by 187 · see citing works

Pharmacological Manipulation of Kynurenic Acid

Erhardt, S., Olsson, S. K., & Engberg, G. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00001 · Cited by 165 · see citing works

Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders

van Velzen, L. S., Vriend, C., de Wit, S. J., & van den Heuvel, O. A. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00419 · Cited by 159 · see citing works

EPS Profiles: The Atypical Antipsychotics

Weiden, P. J. (2007) · Journal of Psychiatric Practice · doi:10.1097/00131746-200701000-00003 · Cited by 152 · see citing works

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia

Arnsten, A., Girgis, R. R., Gray, D. L., & Mailman, R. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.028 · Cited by 144 · see citing works

Distinct cortical and striatal actions of a β-arrestin–biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties

Urs, N. M., Gee, S. M., Pack, T. F., McCorvy, J. D., Evron, T., Snyder, J. C., Yang, X., Rodriguiz, R. M., Borrelli, E., Wetsel, W. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614347113 · Cited by 142 · see citing works

Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway

Renard, J., Loureiro, M., Rosen, L. G., Zunder, J. S., Oliveira, C. D., Schmid, S., Rushlow, W. J., & Laviolette, S. R. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3387-15.2016 · Cited by 131 · see citing works

New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy

Urs, N., Peterson, S. M., & Caron, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.10.011 · Cited by 114 · see citing works

Antipsychotic drug action: antagonism, inverse agonism or partial agonism

STRANGE, P. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.009 · Cited by 109 · see citing works

COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review

Schacht, J. P. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.43 · Cited by 107 · see citing works

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

Kokkinou, M., Irvine, E. E., Bonsall, D. R., Natesan, S., Wells, L. A., Smith, M., Glegola, J. A., Paul, E. J., Tossell, K., Veronese, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0740-6 · Cited by 105 · see citing works

Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area

Schwieler, L., Linderholm, K. R., Nilsson-Todd, L. K., Erhardt, S., & Engberg, G. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.05.014 · Cited by 94 · see citing works

The orphan GPCR, GPR88, modulates function of the striatal dopamine system: A possible therapeutic target for psychiatric disorders?

Logue, S. F., Grauer, S. M., Paulsen, J. E., Graf, R., Taylor, N., Sung, M.-L. A., Zhang, L., Hughes, Z. A., Pulito, V. L., Liu, F., et al. (2009) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.09.007 · Cited by 93 · see citing works

The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials

Prentice, K. J., Gold, J. M., & Buchanan, R. W. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.015 · Cited by 92 · see citing works

PET and SPECT Imaging in Psychiatric Disorders

Zipursky, R. B., Meyer, J. H., & Verhoeff, N. P. L. G. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200303 · Cited by 91 · see citing works

Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action

Urs, N. M., Snyder, J. C., Jacobsen, J. P. R., Peterson, S. M., & Caron, M. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215489109 · Cited by 91 · see citing works

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

Mu, Q., Johnson, K. A., Morgan, P. S., Grenesko, E. L., Molnar, C., Anderson, B. S., Nahas, Z. H., Kozel, F. A., Köse, S., Knable, M. B., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.033 · Cited by 85 · see citing works

Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism

Vauquelin, G., Bostoen, S., Vanderheyden, P., & Seeman, P. M. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0734-2 · Cited by 80 · see citing works

S33138 (N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects

Millan, M. J., Loiseau, F., Dekeyne, A., Gobert, A., Flik, G., Cremers, T. I. F. H., Rivet, J., Sicard, D., Billiras, R., & Brocco, M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.134536 · Cited by 79 · see citing works

Impaired implicit learning in schizophrenia.

Horan, W. P., Green, M. F., Knowlton, B. J., Wynn, J. K., Mintz, J., & Nuechterlein, K. H. (2008) · Neuropsychology · doi:10.1037/a0012602 · Cited by 79 · see citing works

Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects

Jafari, S., Fernandez, F., & Huang, X. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07590.x · Cited by 76 · see citing works

Molecular Neuroimaging: From Conventional to Emerging Techniques

Hammoud, D. A., Hoffman, J. M., & Pomper, M. G. (2007) · Radiology · doi:10.1148/radiol.2451060731 · Cited by 72 · see citing works

Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance

Maggio, R., & Millan, M. J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.001 · Cited by 73 · see citing works

Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant

Hwang, R., Zai, C. C. H., Tiwari, A. K., Müller, D., Arranz, M. J., Morris, A. G., McKenna, P. J., Munro, J., Potkin, S. G., Lieberman, J. A., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.65 · Cited by 71 · see citing works

Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis

Ansell, B. R. E., Dwyer, D., Wood, S. J., Bora, E., Brewer, W. J., Proffitt, T., Velakoulis, D., McGorry, P. D., & Pantelis, C. (2014) · Psychological Medicine · doi:10.1017/s0033291714001652 · Cited by 65 · see citing works

Using pharmacokinetic–pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics

Olsen, C. K., Brennum, L. T., & Kreilgaard, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.005 · Cited by 64 · see citing works

S33138 [N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors

Millan, M. J., la Cour, C. M., Novi, F., Maggio, R., Audinot, V., Newman‐Tancredi, A., Cussac, D., Pasteau, V., Boutin, J. A., Dubuffet, T., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.126706 · Cited by 62 · see citing works

MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant

Shi, S., Leites, C., He, D., Schwartz, D., Moy, W., Shi, J., & Duan, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.535203 · Cited by 61 · see citing works

A Preliminary Attempt to Personalize Risperidone Dosing Using Drug–Drug Interactions and Genetics: Part I

de León, J., Sandson, N. B., & Cozza, K. L. (2008) · Psychosomatics · doi:10.1176/appi.psy.49.3.258 · Cited by 57 · see citing works

Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation

Ahmed, M. R., Gurevich, V. V., Dalby, K. N., Benovic, J., & Gurevich, E. V. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131987 · Cited by 57 · see citing works

Brain‐Derived Neurotrophic Factor in Schizophrenia and Its Relation With Dopamine

Guillin, O., Demily, C., & Thibaut, F. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78012-6 · Cited by 56 · see citing works

The Cognitive Neuropsychology of Auditory Hallucinations: A Parallel Auditory Pathways Framework

Badcock, J. C. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn128 · Cited by 54 · see citing works

Possible role of rare variants in Trace amine associated receptor 1 in schizophrenia

John, J., Kukshal, P., Triptish Bhatia, A., Chowdari, K. V., Nimgaonkar, V. L., Deshpande, S. N., & Thelma, B. K. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.020 · Cited by 54 · see citing works

Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040

Southam, E., Cilia, J., Gartlon, J. E., Woolley, M. L., Lacroix, L. P., Jennings, C. A., Cluderay, J. E., Reavill, C., Rourke, C., Wilson, D. M., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1310-9 · Cited by 54 · see citing works

Insomnia in patients with schizophrenia: current understanding and treatment options

Robertson, I. H., Cheung, A., & Fan, X. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.016 · Cited by 54 · see citing works

Antipsychotic medication and prefrontal cortex activation: A review of neuroimaging findings

Liemburg, E. J., Knegtering, H., Klein, H. C., Kortekaas, R., & Aleman, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.12.008 · Cited by 51 · see citing works

Muscarinic Agonists for the Treatment of Cognition in Schizophrenia

Sellin, A. K., Shad, M. U., & Tamminga, C. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900014048 · Cited by 49 · see citing works

Dopamine D3 receptor antagonists: a patent review (2007 – 2012)

Micheli, F., & Heidbreder, C. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.757593 · Cited by 39 · see citing works

Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138

Millan, M. J., & Brocco, M. (2008) · Therapies · doi:10.2515/therapie:2008041 · Cited by 44 · see citing works

A Preliminary Attempt to Personalize Risperidone Dosing Using Drug–Drug Interactions and Genetics: Part II

de León, J., Sandson, N. B., & Cozza, K. L. (2008) · Psychosomatics · doi:10.1176/appi.psy.49.4.347 · Cited by 43 · see citing works

Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis

Wang, D., Schneider-Thoma, J., Siafis, S., Qin, M., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.03.003 · Cited by 44 · see citing works

New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways

Lodge, D. J., & Perez, S. M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s42708 · Cited by 42 · see citing works

Continuous, but not Intermittent, Antipsychotic Drug Delivery Intensifies the Pursuit of Reward Cues

Bédard, A.-M., Maheux, J., Lévesque, D., & Samaha, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.10 · Cited by 41 · see citing works

Computational cognitive models of prefrontal-striatal-hippocampal interactions in Parkinson’s disease and schizophrenia

Moustafa, A. A., & Gluck, M. A. (2011) · Neural Networks · doi:10.1016/j.neunet.2011.02.006 · Cited by 39 · see citing works

In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles

Assié, M., Domínguez, H., Consul-Denjean, N., & Newman‐Tancredi, A. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0092-z · Cited by 38 · see citing works

Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study

Atalar, F., Acuner, T. T., Çine, N., Öncü, F., Yeşilbursa, D., Özbek, U., & Türkcan, S. (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-27 · Cited by 37 · see citing works

Selective Dopamine D3 Receptor Antagonists: A Review 2001-2005

Micheli, F., & Heidbreder, C. A. (2006) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488906778773634 · Cited by 37 · see citing works

Potential Utility of Biased GPCR Signaling for Treatment of Psychiatric Disorders

Komatsu, H., Fukuchi, M., & Habata, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133207 · Cited by 35 · see citing works

A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics

Tanda, G., Valentini, V., De Luca, M. A., Perra, V., Serra, G. P., & Di Chiara, G. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3780-2 · Cited by 33 · see citing works

Quantifying the inverted U: A meta-analysis of prefrontal dopamine, D1 receptors, and working memory.

Weber, M. A., Conlon, M. M., Stutt, H. R., Wendt, L. H., Eyck, P. T., & Narayanan, N. S. (2022) · Behavioral Neuroscience · doi:10.1037/bne0000512 · Cited by 34 · see citing works

Prefrontal cortical network activity: Opposite effects of psychedelic hallucinogens and D1/D5 dopamine receptor activation

Lambe, E. K., & Aghajanian, G. K. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.12.048 · Cited by 33 · see citing works

Glutamate in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: A Meta-analysis of 1H-Magnetic Resonance Spectroscopy Studies

Kaminski, J. A., Mascarell-Maricic, L., Fukuda, Y., Katthagen, T., Heinz, A., & Schlagenhauf, F. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.09.001 · Cited by 31 · see citing works

A Review of Antipsychotics and Priapism

Hwang, T. I. S., Shah, T., & Sadeghi‐Nejad, H. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.10.003 · Cited by 31 · see citing works

Dopamine Receptor Homooligomers and Heterooligomers in Schizophrenia

Perreault, M., O'Dowd, B., & George, S. R. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00228.x · Cited by 42 · see citing works

Influence of body weight and type of chow on the sensitivity of rats to the behavioral effects of the direct-acting dopamine-receptor agonist quinpirole

Baladi, M. G., Newman, A. H., & France, C. P. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2320-6 · Cited by 31 · see citing works

The Schizophrenia Spectrum Personality Disorders

Chemerinski, E., & Siever, L. J. (2010) · Wiley eBooks · doi:10.1002/9781444327298.ch5 · Cited by 27 · see citing works

A review of the adverse side effects associated with antipsychotics as related to their efficacy.

Pakpoor, J., & Agius, M. A. (2014) · PubMed · Cited by 25 · see citing works

Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action

Zhou, X., Cai, G., Mao, S., Xu, D. M., Xu, X., Zhang, R., & Yao, Z. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02509-z · Cited by 25 · see citing works

Molecular modeling and docking study on dopamine D2-like and serotonin 5-HT2A receptors

Duan, X., Zhang, M., Zhang, X., Wang, F., & Lei, M. (2015) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2015.01.014 · Cited by 24 · see citing works

Gene–gene Interaction Analyses Between NMDA Receptor Subunit and Dopamine Receptor Gene Variants and Clozapine Response

Hwang, R., de Souza, R. P., Tiwari, A. K., Zai, C. C. H., Müller, D. J., Potkin, S. G., Lieberman, J. A., Meltze, H. Y., & Kennedy, J. L. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.182 · Cited by 24 · see citing works

Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication

Strous, R. D., Greenbaum, L., Kanyas, K., Merbl, Y., Horowitz, A., Karni, O., Viglin, D., Olender, T., Deshpande, S. N., Lancet, D., et al. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006651 · Cited by 24 · see citing works

Selective dopamine D3receptor antagonists. A decade of progress: 1997 – 2007

Micheli, F., & Heidbreder, C. A. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.8.821 · Cited by 24 · see citing works

Integrated approaches to understanding antipsychotic drug action at GPCRs

Urs, N. M., NICHOLLS, P. J., & Caron, M. G. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.11.002 · Cited by 23 · see citing works

Maternal deprivation disrupts mitochondrial energy homeostasis in the brain of rats subjected to ketamine-induced schizophrenia

Zugno, A. I., Pacheco, F. D., Budni, J., de Oliveira, M. B., Canever, L., Heylmann, A. S., Wessler, P. G., Silveira, F. D. R., Mastella, G. A., Gonçalves, C. L., et al. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9671-3 · Cited by 23 · see citing works

Maternal Immune Activation Induces Cortical Catecholaminergic Hypofunction and Cognitive Impairments in Offspring

Perez-Palomar, B., Erdozain, A. M., Erkizia-Santamaría, I., Ortega, J. E., & Meana, J. J. (2023) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-023-10070-1 · Cited by 22 · see citing works

Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia

Zugno, A. I., Miranda, I. M., Budni, J., Volpato, A. M., Luca, R. D. D., Deroza, P. F., de Oliveira, M. B., Heylmann, A. S., Silveira, F. D. R., Wessler, P. G., et al. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.05.059 · Cited by 22 · see citing works

Quality of Life and Adverse Effects of Olanzapine Versus Risperidone Therapy in Patients with Schizophrenia

Chaves, K. M., Serrano‐Blanco, A., Ribeiro, S. B., Soares, L. A. L., Guerra, G. C. B., Alves, M. D. S. C. F., Júnior, R. F. D. A., Soares-Rachetti, V. D. P., Júnior, A. F., & de Araújo, A. A. (2012) · Psychiatric Quarterly · doi:10.1007/s11126-012-9233-3 · Cited by 21 · see citing works

The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents

Gentzel, R. C., Toolan, D. M., Roberts, R., Koser, A. J., Kandebo, M., Hershey, J. C., Renger, J. J., Uslaner, J. M., & Smith, S. M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.024 · Cited by 21 · see citing works

Antipsychotic-Associated Mental Side Effects and Their Relationship to Dopamine D2 Receptor Occupancy in Striatal Subdivisions

Kim, J., Son, Y., Kim, H.-K., Lee, S., Cho, S., Kim, Y.-B., & Cho, Z. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318222353a · Cited by 21 · see citing works

Cerebrospinal fluid kynurenic acid in male patients with schizophrenia – correlation with monoamine metabolites

Nilsson-Todd, L., Nordin, C., Jönsson, E., Skogh, E., & Erhardt, S. (2007) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2006.00170.x · Cited by 23 · see citing works

Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials

Antoun, A., Girgis, E., & Mishriky, R. S. L. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000308 · Cited by 20 · see citing works

Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio

Jafari, S., Bouillon, M. E., Huang, X., Pyne, S. G., & Fernandez, F. (2012) · BMC Pharmacology · doi:10.1186/1471-2210-12-8 · Cited by 19 · see citing works

Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy

Li, Y.-W., Seager, M. A., Wojcik, T., Heman, K. L., Molski, T. F. P., Fernandes, A., Langdon, S., Pendri, A., Gerritz, S. W., Tian, Y., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.037 · Cited by 18 · see citing works

Neurochemical imaging in schizophrenia.

Urban, N., & Abi-Dargham, A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_37 · Cited by 19 · see citing works

Contribution of nonprimate animal models in understanding the etiology of schizophrenia

Lazar, N. L., Neufeld, R. W. J., & Cain, D. P. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100054 · Cited by 18 · see citing works

Priapism in Antipsychotic Drug Use: A Rare but Important Side Effect

Sinkeviciute, I., Kroken, R. A., & Johnsen, E. (2012) · Case Reports in Psychiatry · doi:10.1155/2012/496364 · Cited by 18 · see citing works

Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation

Etiévant, A., Betry, C., Arnt, J., & Haddjeri, N. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.05.035 · Cited by 17 · see citing works

Dopamine D2/3receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine

Tuppurainen, H., Kuikka, J. T., Viinamäki, H. T., Husso, M., & Tiihonen, J. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01982.x · Cited by 17 · see citing works

The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk

Ferrara, M., Umlauf, A., Sanders, C., Meyer, J. M., McCutchan, J. A., Duarte, N. A., Atkinson, J. H., Grant, I., & Ellis, R. J. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.04.015 · Cited by 17 · see citing works

PET Imaging in Psychiatric Disorders.

Ferrando, R., Hernandes, D., Ghini, B. G., & Coutinho, A. (2025) · Seminars in nuclear medicine · doi:10.1053/j.semnuclmed.2025.06.004 · Cited by 16 · see citing works

A review on synthesis of FDA-approved antipsychotic drugs

Rani, A., Aslam, M., Pandey, G., & Pant, B. N. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133430 · Cited by 16 · see citing works

Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness

Johnsen, E., & Kroken, R. A. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312462275 · Cited by 18 · see citing works

Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment

Chen, K., & Lung, F. (2017) · Psychiatric Quarterly · doi:10.1007/s11126-017-9494-y · Cited by 16 · see citing works

Atypical antipsychotics antagonize GABAA receptors in the ventral tegmental area GABA neurons to relieve psychotic behaviors

Lu, C., Zhu, X., Feng, Y., Ao, W., Li, J., Gao, Z., Luo, H., Chen, M., Cai, F., Zhan, S., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01982-8 · Cited by 15 · see citing works

The novel atypical antipsychotic cariprazine demonstrates dopamine D2receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity

Delcourte, S., Ashby, C. R., Rovera, R., Kiss, B., Adham, N., Farkas, B., & Haddjeri, N. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12867 · Cited by 15 · see citing works

Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents~!2009-12-17~!2010-04-07~!2010-07-20~!

Etiévant, A. (2010) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523801003010001 · Cited by 16 · see citing works

Chronic hyperdopaminergic activity of schizophrenia is associated with increased ΔFosB levels and cdk-5 signaling in the nucleus accumbens.

Cantrup, R., Sathanantham, K., Rushlow, W., & Rajakumar, N. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.07.027 · Cited by 15 · see citing works

Post‐zygotic genomic changes in glutamate and dopamine pathway genes may explain discordance of monozygotic twins for schizophrenia

Castellani, C. A., Melka, M. G., Gui, J. L., Gallo, A. J., O’Reilly, R. L., & Singh, S. M. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0174-1 · Cited by 14 · see citing works

Hypofrontality in schizophrenic patients and its relevance for the choice of antipsychotic medication: An event-related potential study

Ehlis, A., Pauli, P., Herrmann, M. J., Plichta, M. M., Zielasek, J., Pfuhlmann, B., Stöber, G., Ringel, T. M., Jabs, B. E., & Fallgatter, A. J. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.566354 · Cited by 13 · see citing works

Is Rational Antipsychotic Polytherapy Feasible? A Selective Review

Kroken, R. A., & Johnsen, E. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0266-y · Cited by 11 · see citing works

C.09.02 How existing treatments have helped patients and their current limitations – efficacy

Conley, R., Masand, P. S., Kasper, S. F., & Buckley, P. F. (2007) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(07)70950-1

Mecanismos de acción de los medicamentos antipsicóticos de segunda generación en la esquizofrenia: conocimientos obtenidos a partir de los estudios de imágenes cerebrales

Abi‐Dargham, A., & Laruelle, M. A. (2005) · European psychiatry (Ed Española) · doi:10.1017/s1134066500003520

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

Laruelle, M., Frankle, W., Narendran, R., Kegeles, L. S., & Abi-Dargham, A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.017 · Cited by 168 · see citing works

Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis

KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146 · see citing works

New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists

Peng, A., Chai, J., Wu, H., Bai, B., Yang, H., He, W., & Zhao, Y. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s455279 · Cited by 37 · see citing works